AU2005214349B2 - Substituted azole derivatives, compositions, and methods of use - Google Patents

Substituted azole derivatives, compositions, and methods of use Download PDF

Info

Publication number
AU2005214349B2
AU2005214349B2 AU2005214349A AU2005214349A AU2005214349B2 AU 2005214349 B2 AU2005214349 B2 AU 2005214349B2 AU 2005214349 A AU2005214349 A AU 2005214349A AU 2005214349 A AU2005214349 A AU 2005214349A AU 2005214349 B2 AU2005214349 B2 AU 2005214349B2
Authority
AU
Australia
Prior art keywords
phenyl
dichloro
imidazol
biphenyl
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005214349A
Other languages
English (en)
Other versions
AU2005214349A1 (en
Inventor
Robert C. Andrews
Murty N. Arimilli
Adnan M.M. Mjalli
Dharma R. Polisetti
James C. Quada Jr.
Govindan Subramanian
Rongyuan Xie
Ravindra R. Yarragunta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Publication of AU2005214349A1 publication Critical patent/AU2005214349A1/en
Assigned to TRANSTECH PHARMA, INC. reassignment TRANSTECH PHARMA, INC. Request for Assignment Assignors: TRANSTECH PHARMA INC.
Application granted granted Critical
Publication of AU2005214349B2 publication Critical patent/AU2005214349B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005214349A 2004-02-12 2005-02-11 Substituted azole derivatives, compositions, and methods of use Ceased AU2005214349B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54397104P 2004-02-12 2004-02-12
US60/543,971 2004-02-12
PCT/US2005/004590 WO2005080346A1 (en) 2004-02-12 2005-02-11 Substituted azole derivatives, compositions, and methods of use

Publications (2)

Publication Number Publication Date
AU2005214349A1 AU2005214349A1 (en) 2005-09-01
AU2005214349B2 true AU2005214349B2 (en) 2011-11-03

Family

ID=34885991

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005214349A Ceased AU2005214349B2 (en) 2004-02-12 2005-02-11 Substituted azole derivatives, compositions, and methods of use

Country Status (10)

Country Link
US (2) US20050187277A1 (https=)
EP (1) EP1730118A1 (https=)
JP (1) JP4898458B2 (https=)
CN (1) CN1922151A (https=)
AU (1) AU2005214349B2 (https=)
CA (1) CA2551909C (https=)
IL (1) IL176571A0 (https=)
NZ (1) NZ548208A (https=)
WO (1) WO2005080346A1 (https=)
ZA (1) ZA200605526B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557672A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
EP1723120A4 (en) * 2004-03-08 2007-09-26 Wyeth Corp MODULATORS OF THE ION CHANNEL FUNCTION
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
CA2580119A1 (en) 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
CN101193852A (zh) * 2005-02-18 2008-06-04 因诺迪亚有限公司 4-羟基异亮氨酸类似物及其用途
CN101252926A (zh) * 2005-03-22 2008-08-27 因诺迪亚有限公司 用于预防和治疗肥胖症及相关综合征的化合物与组合物
EP1953151A4 (en) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
RU2381225C1 (ru) * 2005-11-24 2010-02-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производное циннамида типа морфолина
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
BRPI0707338A2 (pt) * 2006-01-30 2011-05-03 Transtech Pharma Inc derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR059955A1 (es) * 2006-03-09 2008-05-14 Eisai R&D Man Co Ltd Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
US20100048545A1 (en) * 2006-03-22 2010-02-25 Innodia Inc. Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity
AR062095A1 (es) * 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
JP2010506916A (ja) * 2006-10-20 2010-03-04 メルク エンド カムパニー インコーポレーテッド ボンベシンレセプターサブタイプ３モジュレーターとしての置換イミダゾール
WO2008051406A2 (en) * 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
WO2008051405A1 (en) * 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
JP5313161B2 (ja) * 2006-12-11 2013-10-09 メルク・シャープ・アンド・ドーム・コーポレーション ボンベシンレセプターサブタイプ−３調節因子としての置換ジアゼピンスルホンアミド
AU2008205169B2 (en) * 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
CL2008000582A1 (es) * 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
WO2008140111A1 (ja) * 2007-05-16 2008-11-20 Eisai R & D Management Co., Ltd. シンナミド誘導体のワンポット製造方法
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
ES2529648T3 (es) * 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
US20100317860A1 (en) * 2008-01-28 2010-12-16 Ikuo Kushida Crystalline cinnamide compounds or salts thereof
CN102361857B (zh) * 2008-09-26 2015-09-16 默沙东公司 可用作抗糖尿病剂的环状苯并咪唑衍生物
CN102171382B (zh) * 2008-10-06 2013-08-14 四国化成工业株式会社 2-苄基-4-(2，4-二氯苯基)-5-甲基咪唑化合物
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
EA020017B1 (ru) 2009-04-30 2014-08-29 Новартис Аг Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
JP5368244B2 (ja) * 2009-10-14 2013-12-18 四国化成工業株式会社 ２−（２，４−ジクロロベンジル）−４−アリール−５−メチルイミダゾール化合物
JP5368263B2 (ja) * 2009-11-04 2013-12-18 四国化成工業株式会社 ４−（２，４−ジクロロフェニル）−５−メチルイミダゾール化合物
JP5368271B2 (ja) * 2009-11-20 2013-12-18 四国化成工業株式会社 ４−（４−ビフェニリル）−２−（２，４−ジクロロベンジル）イミダゾールおよび表面処理液
JP5398076B2 (ja) * 2009-12-10 2014-01-29 四国化成工業株式会社 ２−（ブロモベンジル）−４−（ブロモフェニル）−５−メチルイミダゾール化合物
JP5398075B2 (ja) * 2010-01-13 2014-01-29 四国化成工業株式会社 ４−（ジクロロフェニル）−２−（４−フルオロベンジル）−５−メチルイミダゾール化合物
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
ES2532357T3 (es) 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
EP2593433B1 (en) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
SG192126A1 (en) * 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2012139010A1 (en) * 2011-04-08 2012-10-11 University Of Kansas Grp94 inhibitors
JPWO2014123203A1 (ja) * 2013-02-06 2017-02-02 京都薬品工業株式会社 糖尿病治療薬
WO2014209034A1 (en) * 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
WO2015120610A1 (en) * 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
CN109825849B (zh) * 2019-01-25 2021-02-19 华南理工大学 一种三氟甲基乙烯基类化合物的电化学制备方法
ES2999626T3 (en) * 2020-10-09 2025-02-26 Bristol Myers Squibb Co Aminoimidazole fpr2 agonists
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008982A1 (fr) * 1992-10-13 1994-04-28 Nippon Soda Co., Ltd. Derives oxazole et thiazole
WO2000071120A1 (en) * 1999-05-25 2000-11-30 Smithkline Beecham Corporation Antibacterial compounds
JP2002114768A (ja) * 2000-10-11 2002-04-16 Japan Tobacco Inc ２−（２，５−ジハロゲン−３，４−ジヒドロキシフェニル）アゾール化合物及びそれを含有してなる医薬組成物
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
EP1227084A1 (en) * 1999-10-28 2002-07-31 Microcide Pharmaceuticals, Inc. Drug discharge pump inhibitors
EP1253142A1 (en) * 2000-01-24 2002-10-30 Shionogi & Co., Ltd. Compounds exhibiting thrombopoietin receptor agonism
WO2003048140A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP2003231679A (ja) * 2001-12-03 2003-08-19 Japan Tobacco Inc アゾール化合物及びその医薬用途
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
WO2003093263A1 (en) * 2002-05-02 2003-11-13 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
AU2004210711A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546113A (en) * 1983-04-14 1985-10-08 Pfizer Inc. Antiprotozoal diamidines
CA2009925C (en) * 1989-02-14 2002-10-01 Koichi Kondo Method for enhancement of chemiluminescence
DE69330713T2 (de) * 1992-03-13 2002-07-04 Merck Sharp & Dohme Ltd., Hoddesdon Imidazol-, triazol- und tetrazolderivate
ATE202571T1 (de) * 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
DE69635048T2 (de) * 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
US6388076B1 (en) * 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
US6238902B1 (en) * 1996-03-22 2001-05-29 Genentech, Inc. Protein tyrosine phosphatases
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
FR2767527B1 (fr) * 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
WO1999015529A1 (en) * 1997-09-23 1999-04-01 Novo Nordisk A/S MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
CA2331056A1 (en) * 1998-05-12 1999-12-02 Wyeth 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6699896B1 (en) * 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US20030194745A1 (en) * 1998-06-26 2003-10-16 Mcdowell Robert S. Cysteine mutants and methods for detecting ligand binding to biological molecules
JP2004514402A (ja) * 1998-07-24 2004-05-20 メルク　フロスト　カナダ　アンド　カンパニー プロテインチロシンホスファターゼ−１ｂ（ｐｔｐ−１ｂ）欠失マウスおよびその使用
US6174874B1 (en) * 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
AU1543600A (en) * 1998-12-11 2000-07-03 Mcgill University Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
JP4221129B2 (ja) * 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
CA2372116A1 (en) * 1999-05-14 2000-11-23 Claude Dufresne Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
EP1070708B1 (en) * 1999-07-21 2004-01-14 F. Hoffmann-La Roche Ag Triazole derivatives
DE60023920T2 (de) * 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
US6410556B1 (en) * 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
WO2001046204A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
CA2393363A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
AU2335701A (en) * 1999-12-22 2001-07-03 Merck Frosst Canada & Co. Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
US6486142B2 (en) * 1999-12-22 2002-11-26 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
JP2003520049A (ja) * 2000-01-18 2003-07-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトタンパク質であるチロシンホスファターゼのポリヌクレオチド、ポリペプチド、および抗体
AU2001238458A1 (en) * 2000-02-14 2001-08-27 Ceptyr, Inc. Improved assay for protein tyrosine phosphatases
JP2003528106A (ja) * 2000-03-22 2003-09-24 メルク フロスト カナダ アンド カンパニー Ｐｔｐ−１ｂ阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類
US6627647B1 (en) * 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
US6911468B2 (en) * 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
JP2004502754A (ja) * 2000-07-06 2004-01-29 アレー　バイオファーマ　インコーポレイテッド ホスファターゼ阻害剤の調製
US20020099073A1 (en) * 2000-07-07 2002-07-25 Andersen Henrik Sune Modulators of protein tyrosine phosphatases (PTPases)
US6613903B2 (en) * 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US20020169157A1 (en) * 2000-08-29 2002-11-14 Gang Liu Selective protein tyrosine phosphatatase inhibitors
US6972340B2 (en) * 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
US6472545B2 (en) * 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
US20020035137A1 (en) * 2000-08-29 2002-03-21 Gang Liu Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
GB0022079D0 (en) * 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor
US20030108883A1 (en) * 2001-02-13 2003-06-12 Rondinone Cristina M. Methods for identifying compounds that inhibit or reduce PTP1B expression
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
US20030064979A1 (en) * 2001-06-29 2003-04-03 Hansen Thomas Kruse Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
US20030170660A1 (en) * 2001-07-11 2003-09-11 Sondergaard Helle Bach P387L variant in protein tyrosine phosphatase-1B is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro
CA2463441A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
EP1438044A1 (en) * 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
ATE348828T1 (de) * 2001-10-19 2007-01-15 Transtech Pharma Inc Beta-carbolin-derivate als ptp-inhibitoren
US6642381B2 (en) * 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
US20030180827A1 (en) * 2002-01-04 2003-09-25 Aventis Pharma Deutschland Gmbh. Highly sensitive and continuous protein tyrosine phosphatase test using 6,8-difluoro-4-methylumbelliferyl phosphate
US20030215899A1 (en) * 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US6784205B2 (en) * 2002-03-01 2004-08-31 Sunesis Pharmaceuticals, Inc. Compounds that modulate the activity of PTP-1B and TC-PTP
IL164262A0 (en) * 2002-04-03 2005-12-18 Novartis Ag 5-Substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as ptpase 1b inhibitors
WO2003086390A1 (en) * 2002-04-12 2003-10-23 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
AU2003228744A1 (en) * 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
US7399586B2 (en) * 2002-05-23 2008-07-15 Ceptyr, Inc. Modulation of biological signal transduction by RNA interference
ATE323702T1 (de) * 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US6849761B2 (en) * 2002-09-05 2005-02-01 Wyeth Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia
AU2003300447B2 (en) * 2002-12-30 2009-09-03 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
WO2004071448A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
BRPI0707338A2 (pt) * 2006-01-30 2011-05-03 Transtech Pharma Inc derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008982A1 (fr) * 1992-10-13 1994-04-28 Nippon Soda Co., Ltd. Derives oxazole et thiazole
WO2000071120A1 (en) * 1999-05-25 2000-11-30 Smithkline Beecham Corporation Antibacterial compounds
EP1227084A1 (en) * 1999-10-28 2002-07-31 Microcide Pharmaceuticals, Inc. Drug discharge pump inhibitors
EP1253142A1 (en) * 2000-01-24 2002-10-30 Shionogi & Co., Ltd. Compounds exhibiting thrombopoietin receptor agonism
JP2002114768A (ja) * 2000-10-11 2002-04-16 Japan Tobacco Inc ２−（２，５−ジハロゲン−３，４−ジヒドロキシフェニル）アゾール化合物及びそれを含有してなる医薬組成物
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
WO2003048140A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP2003231679A (ja) * 2001-12-03 2003-08-19 Japan Tobacco Inc アゾール化合物及びその医薬用途
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
WO2003093263A1 (en) * 2002-05-02 2003-11-13 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
AU2004210711A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAS Registry number 101341-14-4 *
CAS Registry number 143150-90-7 *
CAS Registry number 143182-51-8 *
CAS Registry number 96271-51-1 *
CAS Registry number 96772-99-5 *
CAS Registry number 96975-63-2 *
CAS Registry number 98016-87-6 *
Cocco, M. T. et al (1992) Il. Farm. 47:229-238 *
Laufer, S. A. et al (2002) J. Med. Chem. 45:4695-4705 *
Lipshutz, B. H. and Hungate, R. W. (1981) J. Org. Chem. 46:1410-1413 *
Meanwell, N. A. et al (1992) J. Med. Chem. 35:3483-3497 *

Also Published As

Publication number Publication date
JP2007523903A (ja) 2007-08-23
NZ548208A (en) 2010-09-30
ZA200605526B (en) 2007-11-28
JP4898458B2 (ja) 2012-03-14
CA2551909A1 (en) 2005-09-01
EP1730118A1 (en) 2006-12-13
US20050187277A1 (en) 2005-08-25
CA2551909C (en) 2011-10-11
CN1922151A (zh) 2007-02-28
IL176571A0 (en) 2006-10-31
AU2005214349A1 (en) 2005-09-01
WO2005080346A1 (en) 2005-09-01
US20110092553A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
AU2005214349B2 (en) Substituted azole derivatives, compositions, and methods of use
AU2004210711B2 (en) Substituted azole derivatives as therapeutic agents
US20040186151A1 (en) Substituted azole derivatives as therapeutic agents
FI108434B (fi) Menetelmõ farmakologisesti vaikuttavien bentsimidatsolijohdannaisten valmistamiseksi
US7459472B2 (en) Aryl and heteroaryl compounds, compositions, and methods of use
AU2007211319B9 (en) Substituted imidazole derivatives and their use as PTPase inhibitors
US20040014778A1 (en) Heteroaryl - fused nitrogen heterocycles as therapeutic agents
US20060276518A1 (en) Aryl and heteroaryl compounds and methods to modulate coagulation
CA2525628C (en) New benzimidazole derivatives
US7115645B2 (en) 1,2 diarylbenzimidazoles and their pharmaceutical use
HRP20050816A2 (hr) Biaril supstituirani triazoli kao blokatori natrijevih kanala
HRP940346A2 (en) Imidazole 5-position substituted angiotensin ii antagonists
US6875765B2 (en) Arylsulfonamide ethers, and methods of use thereof
US7582673B2 (en) Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
EP2190811B1 (en) Renin inhibitors
KR20230116511A (ko) 벤즈옥사지논 유도체 및 그를 포함하는 약제학적 조성물
KR20230132191A (ko) Grk5 억제용 화합물, 이의 제조방법 및 이를 유효성분으로 포함하는 grk5 활성 관련 질환의 예방 또는 치료용 약학 조성물
US20210309616A1 (en) Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors
HUP0002054A2 (hu) N-4-(nitro-metil-szulfonil)-fenil-alkánamid és -benzolszulfonamid-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
JP2002255799A (ja) シクロブテン誘導体を含有する医薬組成物

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: TRANSTECH PHARMA, INC.

Free format text: FORMER NAME: TRANSTECH PHARMA INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired